Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Overexpression of CLN3 contributes to tumour progression and predicts poor prognosis in hepatocellular carcinoma.

Xu Y, Wang H, Zeng Y, Tian Y, Shen Z, Xie Z, Chen F, Sun L, Shu R, Li PP, Chen C, Yu J, Wang K, Luo H.

Surg Oncol. 2019 Mar;28:180-189. doi: 10.1016/j.suronc.2018.12.003. Epub 2018 Dec 20.

PMID:
30851897
2.

CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma.

Zheng H, Jiang WH, Tian T, Tan HS, Chen Y, Qiao GL, Han J, Huang SY, Yang Y, Li S, Wang ZG, Gao R, Ren H, Xing H, Ni JS, Wang LH, Ma LJ, Zhou WP.

Oncotarget. 2017 Mar 21;8(12):18872-18884. doi: 10.18632/oncotarget.14770.

3.

Overexpression of CHKA contributes to tumor progression and metastasis and predicts poor prognosis in colorectal carcinoma.

Hu L, Wang RY, Cai J, Feng D, Yang GZ, Xu QG, Zhai YX, Zhang Y, Zhou WP, Cai QP.

Oncotarget. 2016 Oct 11;7(41):66660-66678. doi: 10.18632/oncotarget.11433.

4.

Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.

Chen D, Chen Y, Yan Y, Pan J, Xing W, Li Q, Zeng W.

BMC Cancer. 2017 Aug 18;17(1):553. doi: 10.1186/s12885-017-3541-9.

5.

HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.

Xu J, Zhang X, Wang H, Ge S, Gao T, Song L, Wang X, Li H, Qin Y, Zhang Z.

Biomed Pharmacother. 2017 Apr;88:421-429. doi: 10.1016/j.biopha.2017.01.013. Epub 2017 Jan 22.

PMID:
28122307
6.

EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis.

Gu F, Yuan S, Liu L, Zhu P, Yang Y, Pan Z, Zhou W.

J Cell Mol Med. 2019 Apr 7. doi: 10.1111/jcmm.14309. [Epub ahead of print]

7.

Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.

Yu B, Ding Y, Liao X, Wang C, Wang B, Chen X.

Dig Dis Sci. 2019 Apr 4. doi: 10.1007/s10620-019-05608-4. [Epub ahead of print]

PMID:
30949905
8.

Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.

Zhang B, Deng C, Wang L, Zhou F, Zhang S, Kang W, Zhan P, Chen J, Shen S, Guo H, Zhang M, Wang Y, Zhang F, Zhang W, Xiao J, Kong B, Friess H, Zhuge Y, Yan H, Zou X.

Mol Carcinog. 2018 Feb;57(2):201-215. doi: 10.1002/mc.22747. Epub 2017 Nov 6.

PMID:
29027712
9.

Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.

Zhang MH, Niu H, Li Z, Huo RT, Wang JM, Liu J.

Cancer Biomark. 2018;23(1):33-43. doi: 10.3233/CBM-181277.

PMID:
29991125
10.

Overexpression of Dickkopf-1 predicts poor prognosis for patients with hepatocellular carcinoma after orthotopic liver transplantation by promoting cancer metastasis and recurrence.

Huang Y, Yang X, Zhao F, Shen Q, Wang Z, Lv X, Hu B, Yu B, Fan J, Qin W.

Med Oncol. 2014 Jul;31(7):966. doi: 10.1007/s12032-014-0966-8. Epub 2014 May 31.

PMID:
24878698
11.

Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma.

Zhang B, Dong LW, Tan YX, Zhang J, Pan YF, Yang C, Li MH, Ding ZW, Liu LJ, Jiang TY, Yang JH, Wang HY.

Br J Cancer. 2013 Jul 9;109(1):14-23. doi: 10.1038/bjc.2013.293. Epub 2013 Jun 13.

12.

A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.

Zhu P, Jin J, Liao Y, Li J, Yu XZ, Liao W, He S.

Oncotarget. 2015 Dec 1;6(38):41383-97. doi: 10.18632/oncotarget.5510.

13.

Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)‑2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway.

Li X, Yang Z, Song W, Zhou L, Li Q, Tao K, Zhou J, Wang X, Zheng Z, You N, Dou K, Li H.

Int J Oncol. 2013 Sep;43(3):793-802. doi: 10.3892/ijo.2013.1992. Epub 2013 Jun 26.

PMID:
23807724
14.

Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a.

Xie C, Song LB, Wu JH, Li J, Yun JP, Lai JM, Xie DY, Lin BL, Yuan YF, Li M, Gao ZL.

PLoS One. 2012;7(7):e40607. doi: 10.1371/journal.pone.0040607. Epub 2012 Jul 16.

15.

Aldolase B inhibits metastasis through Ten-Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma.

Tao QF, Yuan SX, Yang F, Yang S, Yang Y, Yuan JH, Wang ZG, Xu QG, Lin KY, Cai J, Yu J, Huang WL, Teng XL, Zhou CC, Wang F, Sun SH, Zhou WP.

Mol Cancer. 2015 Sep 17;14:170. doi: 10.1186/s12943-015-0437-7.

16.

Oncogenic function and prognostic significance of Abelson interactor 1 in hepatocellular carcinoma.

Wang JL, Yan TT, Long C, Cai WW.

Int J Oncol. 2017 May;50(5):1889-1898. doi: 10.3892/ijo.2017.3920. Epub 2017 Mar 20.

PMID:
28339046
17.

PRSS8 is Downregulated and Suppresses Tumour Growth and Metastases in Hepatocellular Carcinoma.

Zhang L, Jia G, Shi B, Ge G, Duan H, Yang Y.

Cell Physiol Biochem. 2016;40(3-4):757-769. Epub 2016 Dec 5.

18.

Overexpression of Zwint predicts poor prognosis and promotes the proliferation of hepatocellular carcinoma by regulating cell-cycle-related proteins.

Ying H, Xu Z, Chen M, Zhou S, Liang X, Cai X.

Onco Targets Ther. 2018 Feb 2;11:689-702. doi: 10.2147/OTT.S152138. eCollection 2018.

19.

CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma.

Li L, Xu L, Yan J, Zhen ZJ, Ji Y, Liu CQ, Lau WY, Zheng L, Xu J.

J Exp Clin Cancer Res. 2015 Oct 26;34:129. doi: 10.1186/s13046-015-0247-1.

20.

Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation.

Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH.

J Cancer Res Clin Oncol. 2012 Jan;138(1):153-61. doi: 10.1007/s00432-011-1076-z. Epub 2011 Nov 10.

PMID:
22071603

Supplemental Content

Support Center